Wednesday, July 8, 2026

biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON

CG Oncology

CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carci

Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
Status
Public
HQ
Dallas, USA
Founded
2010
Employees
187
Programs
8
Drugs
1
Patents
5
Clinical program

CG0070

Phase 2 · mab · Bladder Cancer

CG0070 for Bladder Cancer is a Phase 2 program (mab) at CG Oncology with 1 ClinicalTrials.gov record(s).

← All CG Oncology projects Phase 2 mab completed

Internal code BOND 2 version 3.8

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CG Oncology
Phase
Phase 2
Modality
mab
Indication
Bladder Cancer
Status
completed
Trials
1

Clinical trials